Baxter International Inc. Securities Fraud Investigation

Shamis & Gentile, P.A. reminds investors of the upcoming lead plaintiff deadline of December 15, 2025 in the class action filed on behalf of investors who purchased or otherwise acquired Baxter International Inc. (“Baxter International” or the “Company”) (NYSE: BAX) securities between February 23, 2022 and July 30, 2025 (the “Class Period”).

Investors who purchased Baxter International securities during the Class Period may be eligible to serve as lead plaintiff. Investors suffering losses in excess of $100,000 are advised to contact the firm now for more information on how to participate. The deadline to apply for lead plaintiff is December 15, 2025.

The class action lawsuit alleges that Baxter International and certain executives misled investors about the safety and commercial success of its flagship medical device, the Novum IQ Large Volume Pump (Novum LVP), used to deliver fluids and medications to patients. According to the complaint, Baxter routinely described Novum as a best-in-class platform with advanced safety features and a successful U.S. rollout, while concealing serious, recurring malfunctions. The device suffered from systemic defects, including underinfusion, overinfusion, and complete non-delivery of fluids, which led to 79 serious injuries and two patient deaths.

The complaint further alleges that the “truth” began to emerge in April 2025 when a whistleblower report from a St. Louis hospital system raised concerns about patient safety. Baxter subsequently issued customer warning letters on April 24, 2025 and July 14, 2025 regarding the same risks, and the FDA later classified the issues as a Class I recall, its most serious category. On July 31, 2025, Baxter announced it would voluntarily pause all new Novum IQ sales and installations, while simultaneously admitting it could not provide a timeline for resuming shipments.

On this news, Baxter’s stock price fell 22.4%, from $28.05 on July 30, 2025 to $21.76 on July 31, 2025, substantially harming investors.

Investors who purchased Baxter securities during the Class Period may have important legal rights and are encouraged to act promptly. The deadline to seek appointment as lead plaintiff is December 15, 2025.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.